Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesEarnSquareMore

News

Stay up to date on the latest crypto trends with our expert, in-depth coverage.

banner
Flash
11:49
Despite the existence of an accelerated approval channel, the U.S. Food and Drug Administration (FDA) has decided to delay processing the market applications for nicotine pouch products such as Zyn and Velo.
According to informed sources, regulators are primarily concerned that these products may pose health risks to non-smokers and minors. These tobacco alternatives absorb nicotine directly through the oral mucosa and have rapidly expanded in the US market in recent years. Industry giants British American Tobacco’s Velo and Altria Group-backed Zyn brand originally aimed to accelerate their market launch via the FDA’s “modified risk tobacco product” certification pathway. This mechanism allows companies to gain a marketing advantage by scientifically proving their products are less harmful than traditional cigarettes.However, the FDA review found that nicotine pouches may attract groups who have never used tobacco, especially teenagers. Internal reports indicate that fruity flavors and discreet usage methods can easily lead to misuse by minors. Meanwhile, although tobacco companies like Philip Morris have not directly entered this field, their regulatory experiences with heated tobacco products are now being referenced by peers.Industry insiders analyzed that delays in approval may impact the strategic planning of companies specializing in nicotine pouches, such as Turning Point Brands. While companies emphasize that their products aim to help adult smokers reduce harm, regulators continue to require additional evaluations on secondhand exposure risk and child ingestion prevention. This tug-of-war reflects the difficult balance between public health concerns and business interests for new types of nicotine products.
11:49
According to informed sources, crude oil production at Kazakhstan’s giant Tengiz oilfield saw a significant increase in March, reaching an average daily output of 700,000 barrels, which is a substantial 19% rise compared to February levels.
This production rebound signifies that the oil field operation has gradually overcome the impact of previous production fluctuations. The Tengiz oil field is operated by Chevron, with international energy giants such as ExxonMobil jointly participating in development. It is an important oil and gas production base in Kazakhstan and globally. This rapid climb in output benefits from the smooth completion of facility maintenance work and optimized extraction efficiency. Industry observers point out that the recovery in production not only strengthens Kazakhstan’s supply position in the global energy market, but also provides positive performance support for international energy companies involved in the project. As the summer peak oil demand season approaches, the stable output of this oil field will play a key role in balancing the regional energy supply and demand structure.
11:48
Agenus announced that the first patient has been enrolled in its global Phase III Battman trial.
This trial aims to evaluate the efficacy and safety of the combination therapy of BOT and Bal immunotherapy in patients with metastatic colorectal cancer who are microsatellite stable (MSS) or have proficient mismatch repair (pMMR).
News